- Multi-Specialty CNS Research Center Strengthens Trial Execution and Patient Diversity in Alzheimer's Agitation Study -
POTOMAC, MD / ACCESS Newswire / January 22, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage pharmaceutical company leveraging Artificial Intelligence ("AI") to develop innovative treatments for Alzheimer's disease, today announced the addition of Integrative Clinical Trials, LLC, located in Brooklyn, New York, as a new clinical site participating in the Company's Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer's disease.
Integrative Clinical Trials is a clinical research center conducting studies across a broad range of Central Nervous System ("CNS") disorders, including Alzheimer's disease and mild cognitive impairment. The site is led by Dr. Inna Yuryev-Golger, MD, who serves as Principal Investigator and brings more than 10 years of experience conducting clinical research. Bella Yevseva serves as the Clinical Trial Coordinator.
"Adding Integrative Clinical Trials further strengthens our CALMA clinical network with a site that has deep expertise across CNS disorders," said Ram Mukunda, CEO of IGC Pharma. "Their experience in neuropsychiatric and neurodegenerative research supports our commitment to high-quality data generation and efficient trial execution as we advance IGC-AD1."
Located at 2409 Ocean Avenue, Unit 1F, Brooklyn, New York, Integrative Clinical Trials expands IGC Pharma's presence in a major metropolitan area with access to a diverse patient population. The Company believes that incorporating sites with broad CNS experience is important to supporting enrollment and patient engagement.
IGC-AD1 is an investigational cannabinoid-based investigational therapy being evaluated in a randomized, double-blind, placebo-controlled Phase 2 clinical trial for agitation in patients with Alzheimer's disease. The continued expansion of the CALMA trial's clinical footprint reflects IGC Pharma's strategy to support enrollment and maintain rigorous clinical oversight.
To learn more about the trial and participation, visit https://igcpharma.com/igc-ad1-phase-ii/.
About IGC Pharma (dba IGC):
IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
Contact Information:
Rosalyn Christian / John Nesbett
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/biotechnology/igc-pharma-expands-phase-2-calma-trial-with-new-clinical-trial-site-at-integrative-cl-1129914
